{"id":61139,"date":"2026-03-24T19:33:51","date_gmt":"2026-03-24T11:33:51","guid":{"rendered":"https:\/\/flcube.com\/?p=61139"},"modified":"2026-03-24T19:33:52","modified_gmt":"2026-03-24T11:33:52","slug":"gsks-risvutatug-rezetecan-wins-japan-odd-b7-h3-adc-targets-small-cell-lung-cancer-with-phase-1-durable-responses","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61139","title":{"rendered":"GSK’s Risvutatug Rezetecan Wins Japan ODD \u2013 B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses"},"content":{"rendered":"\n

GlaxoSmithKline (GSK; NYSE: GSK<\/a>)<\/strong> announced that risvutatug rezetecan (Ris-Rez)<\/strong>, a B7-H3-targeted antibody-drug conjugate (ADC)<\/strong>, received Orphan Drug Designation (ODD)<\/strong> from Japan’s Ministry of Health, Labour and Welfare<\/strong> for the treatment of small-cell lung cancer (SCLC)<\/strong>. The designation, supported by durable responses<\/strong> observed in the Phase 1 ARTEMIS-001 trial<\/strong> in extensive-stage SCLC (ES-SCLC)<\/strong>, advances GSK’s global development of the Hansoh Pharma-licensed ADC<\/strong>, with a Phase 3 pivotal trial already underway<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>Japan Ministry of Health, Labour and Welfare (MHLW)<\/td><\/tr>
Designation<\/strong><\/td>Orphan Drug Designation (ODD)<\/strong><\/td><\/tr>
Product<\/strong><\/td>Risvutatug rezetecan (Ris-Rez) \u2013 B7-H3-targeted ADC<\/td><\/tr>
Developer<\/strong><\/td>GlaxoSmithKline (GSK; NYSE: GSK)<\/td><\/tr>
Indication<\/strong><\/td>Small-cell lung cancer (SCLC)<\/td><\/tr>
Supporting Data<\/strong><\/td>Phase 1 ARTEMIS-001 \u2013 durable responses in ES-SCLC patients<\/td><\/tr>
Global Rights<\/strong><\/td>Worldwide ex-China<\/strong> (licensed from Hansoh Pharma)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Ris-Rez Specification<\/th><\/tr><\/thead>
Target<\/strong><\/td>B7-H3 (CD276)<\/strong> \u2013 immune checkpoint protein overexpressed in SCLC and other solid tumors<\/td><\/tr>
Format<\/strong><\/td>Antibody-drug conjugate (ADC)<\/strong> \u2013 fully human anti-B7-H3 mAb + topoisomerase inhibitor payload<\/td><\/tr>
Mechanism<\/strong><\/td>Targeted delivery of cytotoxic payload to B7-H3-expressing cancer cells<\/td><\/tr>
Development Origin<\/strong><\/td>Licensed from Hansoh Pharma<\/strong> (China) \u2013 GSK acquired exclusive worldwide rights ex-Greater China<\/strong><\/td><\/tr>
Clinical Stage<\/strong><\/td>Phase 3 global trial ongoing<\/strong> (NCT07099898)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Development Status<\/h2>\n\n\n\n
Study<\/th>Phase<\/th>Population<\/th>Status<\/th>Key Finding<\/th><\/tr><\/thead>
ARTEMIS-001<\/strong><\/td>Phase 1<\/td>Extensive-stage SCLC (ES-SCLC)<\/td>Completed\/enrolling<\/td>Durable responses<\/strong> supporting Japan ODD<\/td><\/tr>
NCT07099898<\/strong><\/td>Phase 3<\/td>Relapsed ES-SCLC<\/td>Ongoing since August 2025<\/strong><\/td>Global pivotal trial for registration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
SCLC Unmet Need<\/strong><\/td>~15% of lung cancers<\/strong>; 5-year survival <7%<\/strong>; ES-SCLC median survival ~12 months<\/strong> with standard chemo-immunotherapy; desperate need for effective second-line+ therapies<\/td><\/tr>
B7-H3 Target Validation<\/strong><\/td>Highly expressed in >65% of SCLC<\/strong>; less prone to resistance vs. DLL3 (tarlatamab target); dual targeting opportunity<\/td><\/tr>
GSK Oncology Strategy<\/strong><\/td>ADC portfolio expansion following Blenrep (BCMA-ADC) withdrawal; Ris-Rez anchors lung cancer ADC franchise<\/strong> with potential for B7-H3 solid tumor expansion<\/strong> (prostate, esophageal)<\/td><\/tr>
Japan Market Access<\/strong><\/td>ODD provides 10-year market exclusivity<\/strong>, tax incentives<\/strong>, priority review<\/strong> \u2013 critical for early launch in high-burden SCLC market<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Tarlatamab (Amgen, DLL3 BiTE) approved 2024; Ris-Rez positions as ADC alternative<\/strong> with potentially improved durability and CNS penetration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n